论文部分内容阅读
目的对子宫腺肌病治疗中应用单纯子宫腺肌病病灶切除术后联合促性腺激素释放激素激动剂的临床疗效进行分析。方法选取子宫腺肌瘤患者50例,将50例患者随机分为两组,对照组24例接受单纯子宫腺肌病病灶切除术治疗,观察组26例在病灶切除术后于第1次月经时在第1~3天给予患者亮丙瑞林注射液治疗,隔28 d治疗1次,连续治疗3次,对比两组临床疗效。结果两组患者治疗后痛经VAS评分均有显著下降,且观察组治疗后VAS评分显著低于对照组,治疗总有效率显著高于对照组,复发率显著低于对照组(P<0.05)。结论在子宫腺肌病治疗中,单纯子宫腺肌病病灶切除术后联合促性腺激素释放激素激动剂可促使治疗效果显著提高,有效改善患者生活质量,值得在临床中推广。
Objective To analyze the clinical efficacy of combined gonadotropin-releasing hormone agonist after resection of adenomyosis in adenomyosis. Methods Fifty patients with adenomyoma were selected and 50 patients were randomly divided into two groups. The control group, 24 patients underwent adenomyosis resection, the observation group, 26 patients after the resection of the lesion in the first menstruation Patients were treated with leuprorelin injection on days 1 to 3 and once every 28 days for 3 consecutive treatments, and the clinical efficacy was compared between the two groups. Results The VAS scores of dysmenorrhea were significantly decreased in both groups after treatment. The VAS score of the observation group was significantly lower than that of the control group. The total effective rate was significantly higher than that of the control group. The recurrence rate was significantly lower than that of the control group (P <0.05). Conclusions In the treatment of adenomyosis, combined with gonadotropin-releasing hormone agonist after focal resection of adenomyosis can promote the treatment effect significantly and effectively improve the quality of life of patients, which is worth to be popularized in clinic.